causal

Lowering the evidence bar adds uncertainty, not just speed

There are two ways to speed drugs to market: streamlining trials to accrue more patients per unit time, which is genuine speed, or lowering the evidence hurdle for approval, which is not just speed but added uncertainty—approving a drug that may or may not work—and empirical work suggests lowering the bar does not actually improve speed as much as assumed because of the technical nature of surrogate endpoints.

causalpending

Speaker

Vinay Prasad

Evidence Quote

“we have actually done some empirical work, where we argue that lowering the evidence hurdle doesn't really improve speed as much as you might think”

Source

Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant— EconTalk
Created: 6/13/2026, 12:28:36 AM

Your notes

Loading notes...